Molding of pharmaceutical materials and/or excipients occurs through spontaneous filling of the cavities through capillary forces, with no formation of an interconnecting “flash” layer of material between the cavities (Figures 1(b) and 1(c)). The particles are solidified (Figure 1(d)) and removed from the mold by bringing the mold in contact with an Cisplatin order adhesive layer that enables the particles to be easily removed from the mold cavities (Figure 1(e)). Inhibitors,research,lifescience,medical At this point free flowing powders or stable dispersions can be obtained by dissolving away the adhesive layer from the particles, with the option to then be further purified, chemically modified, or analyzed (Figure 1(f)). Particles can

be used as suspensions or dried using evaporation or lyophilization to produce

dry powders. Figure 1 Schematic illustration of the PRINT process. (a) Features on a hard silicon master template are replicated with high fidelity (b) to obtain a soft, polymeric mold with micro- Inhibitors,research,lifescience,medical and nanocavities that can then be (c) filled with relevant particle matrix and … 2.2. Fabrication of Particles for Respiratory Drug Delivery PRINT particles were fabricated and isolated as dry powders as described in previous reports [12, 13, 15, 17, 18]. To highlight the chemical versatility of PRINT particle technology for aerosol delivery of both small molecule and biologic drugs, particles comprised of proteins such Inhibitors,research,lifescience,medical as bovine Inhibitors,research,lifescience,medical serum selleck inhibitor albumin (BSA, Sigma-Aldrich) and immunoglobulin G (IgG, Calbiochem), polymers such as poly-lactic-co-glycolic acid (PLGA, Mw 30K, Polysciences), and pharmaceutically relevant compounds such as itraconazole (Spectrum Chemical), zanamivir (Haorui USA), DNase (Worthington Biochemical), and siRNA (Dharmacon) were fabricated. Monodisperse particles from these molds were collected in various aqueous and organic suspensions: for particles consisting of non-water-soluble matrices, such as polymeric and the small molecule itraconazole,

distilled water was used to collect the particles from the array; for particles Inhibitors,research,lifescience,medical consisting of water-soluble matrices such as zanamivir, DNase, and siRNA, isopropyl alcohol was used to collect the particles from the array. To make porous particles, sacrificial poly(vinylpyrrolidone) porogen are comolded with the drug or drug/excipient blend and selectively removed during the harvesting step. Finally, particles were lyophilized from water or tert-butanol in order to obtain dry powder PRINT particles. Itraconazole Cilengitide powder (Spectrum Chemical) was micronized for aerodynamic particle size comparison testing with PRINT particles. Micronization was performed using one pass through the Glen Mills Laboratory Jet Mill. 2.3. Chemical and Bioactivity Analyses of Pharmaceutical Compounds in PRINT Particles PRINT particles composed of small molecules and biologic materials were analyzed to confirm retention of chemical structure and biological activity during the PRINT process.